Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
|
|
Oyster Point Pharma, Inc. (OYST)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 01/13/2023 |
SC 13D/A
| Versant Venture Capital VI, L.P. reports a 0% stake in OYSTER POINT PHARMA, INC. |
| 01/09/2023 |
SC 13D/A
| New Enterprise Associates 14, L.P. has filed a Schedule 13D for Oyster Point Pharma, Inc. |
| 01/05/2023 |
SC 13D/A
| InvOpps IV US, L.P. reports a 0% stake in Oyster Point Pharma, Inc. |
| 12/20/2022 |
SC 13D/A
| InvOpps IV US, L.P. reports a 10.3% stake in Oyster Point Pharma, Inc. |
| 11/21/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 01/13/2022 |
SC 13D/A
| Versant Venture Capital VI, L.P. reports a 8.5% stake in OYSTER POINT PHARMA, INC. |
| 10/27/2021 |
SC 13D/A
| Versant Venture Capital VI, L.P. reports a 8.6% stake in OYSTER POINT PHARMA, INC. |
| 05/24/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/05/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/01/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
|
|